Bristol-Myers Squibb Company
General ticker "BMY" information:
- Sector: Health Care
- Industry: Drug Manufacturers - General
- Capitalization: $103.6B (TTM average)
Bristol-Myers Squibb Company follows the US Stock Market performance with the rate: 12.6%.
Estimated limits based on current volatility of 1.5%: low 60.19$, high 62.07$
Factors to consider:
- Company included in S&P500 list
- Company pays dividends (quarterly): last record date 2026-01-02, amount 0.63$ (Y4.18%)
- Total employees count: 34100 (0.0%) as of 2024
- US accounted for 70.6% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Pricing pressures, Regulatory and compliance, Third-party risks, Pipeline and product risks, Liquidity and credit risks
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [42.70$, 64.88$]
- 2026-12-31 to 2027-12-31 estimated range: [44.92$, 68.08$]
Financial Metrics affecting the BMY estimates:
- Negative: with PPE of 8.8 at the end of fiscal year the price was high
- Positive: Operating profit margin, % of 26.34 > 18.38
- Positive: 6.64 < Operating cash flow per share per price, % of 12.81
- Positive: Inventory ratio change, % of 0.26 <= 0.80
- Positive: Industry operating profit margin (median), % of 26.76 > 9.59
- Positive: 19.40 < Shareholder equity ratio, % of 20.52 <= 42.68
- Negative: Industry operating cash flow per share per price (median), % of 6.08 <= 10.29
- Positive: -4.43 < Investing cash flow per share per price, % of -3.74
- Positive: Return on assets ratio (scaled to [-100,100]) of 7.26 > 6.11
- Positive: Interest expense per share per price, % of 1.37 <= 3.28
Short-term BMY quotes
Relationship graph
Long-term BMY plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $45,006.00MM | $48,300.00MM | $48,194.00MM |
| Operating Expenses | $36,534.00MM | $38,642.00MM | $35,498.00MM |
| Operating Income | $8,472.00MM | $9,658.00MM | $12,696.00MM |
| Non-Operating Income | $-32.00MM | $-18,037.00MM | $-3,368.00MM |
| Interest Expense | $1,166.00MM | $1,947.00MM | $1,510.00MM |
| R&D Expense | $9,207.00MM | $9,782.00MM | $9,612.00MM |
| Income(Loss) | $8,440.00MM | $-8,379.00MM | $9,328.00MM |
| Taxes | $400.00MM | $554.00MM | $2,272.00MM |
| Profit(Loss)* | $8,025.00MM | $-8,948.00MM | $7,053.00MM |
| Stockholders Equity | $29,430.00MM | $16,335.00MM | $18,473.00MM |
| Inventory | $2,662.00MM | $2,557.00MM | $2,690.00MM |
| Assets | $95,159.00MM | $92,603.00MM | $90,038.00MM |
| Operating Cash Flow | $13,860.00MM | $15,190.00MM | $14,156.00MM |
| Capital expenditure | $1,209.00MM | $1,248.00MM | $1,311.00MM |
| Investing Cash Flow | $-2,295.00MM | $-21,352.00MM | $-4,132.00MM |
| Financing Cash Flow | $-9,416.00MM | $5,127.00MM | $-10,348.00MM |
| Earnings Per Share** | $3.88 | $-4.41 | $3.46 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.